BioPharmSignal logoBioPharmSignal

Biotech News

Vivani Medical, Inc. Announces Pricing of Common Stock Offering

Vivani Medical (VANI)Vivani MedicalFinancing

VANI (VANI) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is vani.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

VANIVivani Medical2026-01-27 21:05 EST

Vivani Medical, Inc. Announces Closing of Common Stock Offering

VANIVivani Medical2026-06-25 11:30 EST

Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management

MLYSMineralys Therapeutics2026-06-03 10:05 EST

Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock

TERNTerns Pharmaceuticals2025-12-10 04:30 EST

Terns Announces Pricing of Upsized $650 Million Public Offering

TERNTerns Pharmaceuticals2025-12-11 21:05 EST

Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

PMCBPharmaCyte Biotech2025-08-20 13:15 EST

PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing

View all latest news

Vivani Medical

Vivani Medical is a drug-delivery company focused on long-acting implantable therapies and diabetes-related applications. Its platform is built around improving how medicines are delivered over time.

Recent company news

VANIVivani Medical2026-07-14 20:03 EST

Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026

VANIVivani Medical2026-07-07 11:35 EST

Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

VANIVivani Medical2026-07-02 12:00 EST

Vivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.

VANIVivani Medical2026-06-26 11:30 EST

Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker

VANIVivani Medical2026-06-25 11:30 EST

Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management

Stock data

Close
1.30 USD
Market cap
112.11M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States